| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
| (Address of Principal Executive Offices) | (Zip Code) | ||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Large accelerated filer | ☐ | x | |||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | |||||||||
| Emerging growth company | |||||||||||
Page | ||||||||
Item 1. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
Item 5. | ||||||||
Item 6. | ||||||||
| 1 | ||
| As of September 30, | As of December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| Assets | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Accounts receivable, net | |||||||||||
| Settlement assets, net | |||||||||||
| Prepaid expenses | |||||||||||
| Other current assets | |||||||||||
| Total current assets | |||||||||||
| Capitalized software, net | |||||||||||
| Property and equipment, net | |||||||||||
| Lease right-of-use assets | |||||||||||
| Deferred tax assets, net | |||||||||||
| Other assets | |||||||||||
| Total assets | $ | $ | |||||||||
| Liabilities and stockholders' equity | |||||||||||
| Accounts payable | $ | $ | |||||||||
| Accrued expenses and other liabilities | |||||||||||
| Borrowings under line of credit | |||||||||||
| Current portion of long-term debt, net of original issue discount and debt issuance costs | |||||||||||
| Lease liabilities, current | |||||||||||
| Settlement liabilities | |||||||||||
| Total current liabilities | |||||||||||
| Lease liabilities, non-current | |||||||||||
| Other liabilities | |||||||||||
| Total liabilities | |||||||||||
| Commitments and contingencies (Note 4) | |||||||||||
| Stockholders' equity: | |||||||||||
Preferred stock, par value $ | |||||||||||
Common stock, par value $ | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | ( | ( | |||||||||
| Total stockholders' equity | |||||||||||
| Total liabilities and stockholders' equity | $ | $ | |||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | |||||
2 | |||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Revenue | $ | $ | $ | $ | |||||||||||||||||||
| Cost of revenue, net | |||||||||||||||||||||||
| Gross margin | |||||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| General and administrative | |||||||||||||||||||||||
| Sales and marketing | |||||||||||||||||||||||
| Total operating expenses | |||||||||||||||||||||||
Income (loss) from operations | ( | ( | ( | ||||||||||||||||||||
| Other income (expenses), net | ( | ( | ( | ||||||||||||||||||||
| Income (loss) before income taxes | ( | ( | ( | ||||||||||||||||||||
| (Provision for) benefit from income taxes | ( | ( | ( | ||||||||||||||||||||
| Net loss | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
| Net loss per share: | |||||||||||||||||||||||
| Basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
| Weighted average shares of common stock used to compute net loss per share: | |||||||||||||||||||||||
| Basic and diluted | |||||||||||||||||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | |||||
| 3 | |||||
| Preferred stock | Common stock | Additional paid-in capital | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Three months ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2024 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock on exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised stock options | — | — | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||
| Issuance of common stock under Matching Plan | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with restricted stock units vesting | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Repurchase and retirement of common stock | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2024 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | ||
4 | ||
| Preferred stock | Common stock | Additional paid-in capital | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Three months ended September 30, 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2023 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised stock options | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||
| Issuance of common stock under Matching Plan | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with restricted stock units vesting | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shares withheld from common stock issued to pay employee payroll taxes | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2023 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | ||
5 | ||
| Preferred stock | Common stock | Additional paid-in capital | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Nine months ended September 30, 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2023 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock on exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Repurchases of early exercised stock options | — | — | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||
| Issuance of common stock under Matching Plan | — | — | — | |||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with restricted stock units vesting | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Repurchase and retirement of common stock | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2024 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | ||
6 | ||
| Preferred stock | Common stock | Additional paid-in capital | Accumulated deficit | Total stockholders' equity | ||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||
| Nine months ended September 30, 2023 | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2022 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Vesting of early exercised stock options | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Repurchase of early exercised stock options | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||
| Issuance of common stock under Matching Plan | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with restricted stock units vesting | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||
| Shares withheld from common stock issued to pay employee payroll taxes | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||
Repurchase and retirement of common stock | — | — | ( | — | ( | ( | ( | |||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2023 | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | ||
7 | ||
| Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | ( | $ | ( | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | |||||||||||
| Reduction of operating lease right-of-use assets | |||||||||||
| Loss on impairment, receivables and sale or disposal of equipment | |||||||||||
| Stock-based compensation expense | |||||||||||
| Amortization of original issue discount and debt issuance costs | |||||||||||
| Deferred tax assets | ( | ( | |||||||||
| Changes in assets and liabilities: | |||||||||||
| Accounts receivable, net | |||||||||||
| Settlement assets, net | ( | ( | |||||||||
| Prepaid expenses | |||||||||||
| Other current assets | ( | ||||||||||
| Other assets | ( | ( | |||||||||
| Accounts payable | ( | ||||||||||
| Accrued expenses and other liabilities | ( | ||||||||||
| Operating lease liabilities | ( | ||||||||||
| Settlement liabilities | |||||||||||
| Other liabilities | |||||||||||
| Net cash provided by operating activities | |||||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of property and equipment | ( | ||||||||||
| Software development costs | ( | ( | |||||||||
| Net cash used in investing activities | ( | ( | |||||||||
| Cash flows from financing activities: | |||||||||||
| Principal payments of finance leases | ( | ( | |||||||||
| Principal payments of outstanding debt | ( | ( | |||||||||
| Payments for debt issuance costs | ( | ||||||||||
| Repurchases of early exercised stock options | ( | ( | |||||||||
| Proceeds from common stock purchased under Matching Plan | |||||||||||
| Proceeds from issuance of common stock on exercise of stock options | |||||||||||
| Payments for employee taxes withheld from stock-based awards | ( | ||||||||||
| Repurchase and retirement of common stock | ( | ( | |||||||||
| Net cash used in financing activities | ( | ( | |||||||||
| Net decrease in cash and cash equivalents and restricted cash | ( | ( | |||||||||
| Cash and cash equivalents and restricted cash, beginning of period | |||||||||||
| Cash and cash equivalents and restricted cash, end of period | $ | $ | |||||||||
| Supplemental disclosure of cash flow information: | |||||||||||
| Cash paid for interest | $ | $ | |||||||||
| Cash paid for income taxes | $ | $ | |||||||||
| Noncash investing and financing items: | |||||||||||
| Stock-based compensation capitalized as software development costs | $ | $ | |||||||||
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | $ | $ | |||||||||
| Right-of-use assets acquired through operating leases | $ | $ | |||||||||
| Right-of-use assets acquired through finance leases | $ | $ | |||||||||
| Reconciliation of cash and cash equivalents and restricted cash to the Condensed Consolidated Balance Sheets | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Restricted cash included in other current assets | |||||||||||
| Restricted cash included in settlement assets, net | |||||||||||
| Total cash, cash equivalents and restricted cash | $ | $ | |||||||||
| See accompanying notes to Condensed Consolidated Financial Statements. | |||||
8 | |||||
9 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| United States | $ | $ | $ | $ | |||||||||||||||||||
| All other locations | |||||||||||||||||||||||
| Total revenue | $ | $ | $ | $ | |||||||||||||||||||
10 | ||
11 | ||
| As of September 30, | As of December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| Expensify Card posted collateral for funds held for customers | $ | $ | |||||||||
| Expensify.org restricted cash | |||||||||||
Earned interchange restricted cash | |||||||||||
| Cash in transit for funds held for customers | |||||||||||
| Deferred contract acquisition costs | |||||||||||
| Income tax receivable | |||||||||||
Other restricted cash | |||||||||||
| Expensify Payments LLC restricted cash | |||||||||||
| Other | |||||||||||
| Other current assets | $ | $ | |||||||||
| As of September 30, | As of December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| Capitalized software development costs | $ | $ | |||||||||
| Less: accumulated amortization | ( | ( | |||||||||
| Capitalized software, net | $ | $ | |||||||||
12 | ||
| As of September 30, | As of December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| Computers and equipment | $ | $ | |||||||||
| Furniture and fixtures | |||||||||||
| Leasehold improvements | |||||||||||
| Commercial building | |||||||||||
| Land | |||||||||||
| Construction in progress | |||||||||||
| Total property and equipment | |||||||||||
| Less: accumulated depreciation | ( | ( | |||||||||
| Property and equipment, net | $ | $ | |||||||||
13 | ||
| As of September 30, | As of December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| Sales, payroll and other taxes payable | $ | $ | |||||||||
| Professional fees | |||||||||||
| Partner payouts and advertising fees | |||||||||||
| Cashback rewards | |||||||||||
Matching Plan payroll liability | |||||||||||
| Income taxes payable | |||||||||||
| Restricted common stock liability for early stock option exercises | |||||||||||
| Credit card processing fees | |||||||||||
| Accrued expense reports | |||||||||||
| Commissions payable | |||||||||||
| Hosting and license fees | |||||||||||
| Interest payable | |||||||||||
| Other | |||||||||||
| Accrued expenses and other liabilities | $ | $ | |||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Finance lease cost: | |||||||||||||||||||||||
| Amortization of ROU assets | $ | $ | $ | $ | |||||||||||||||||||
| Interest on lease liabilities | |||||||||||||||||||||||
| Total finance lease cost | |||||||||||||||||||||||
| Operating lease cost | |||||||||||||||||||||||
| Total lease cost | $ | $ | $ | $ | |||||||||||||||||||
14 | ||
| As of September 30, | As of December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| $ | $ | ||||||||||
| $ | $ | ||||||||||
| Weighted average remaining lease term (in years): | |||||||||||
| Finance leases | |||||||||||
| Operating leases | |||||||||||
| Weighted average discount rate: | |||||||||||
| Finance leases | % | % | |||||||||
| Operating leases | % | % | |||||||||
| Nine months ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash paid for amounts included in the measurement of lease liabilities: | |||||||||||
| Operating cash flows from operating leases | $ | ( | $ | ( | |||||||
| Operating cash flows from finance leases | $ | ( | $ | ( | |||||||
| Financing cash flows from finance leases | $ | ( | $ | ( | |||||||
| For the year ending: | Finance leases | Operating leases | |||||||||
| Remainder of 2024 | $ | $ | |||||||||
| 2025 | |||||||||||
| 2026 | |||||||||||
| 2027 | |||||||||||
| 2028 | |||||||||||
| Thereafter | |||||||||||
| Total future lease payments | |||||||||||
| Less: imputed interest | ( | ( | |||||||||
| ( | ( | ||||||||||
| $ | $ | ||||||||||
15 | ||
16 | ||
17 | ||
18 | ||
19 | ||
20 | ||
| Class A Common Stock | LT50 Common Stock | Weighted average grant date fair value per share | |||||||||||||||
Outstanding at December 31, 2023 | $ | ||||||||||||||||
| RSUs granted | $ | ||||||||||||||||
| RSUs vested | ( | ( | $ | ||||||||||||||
| RSUs cancelled/forfeited/expired | ( | ( | $ | ||||||||||||||
Outstanding at September 30, 2024 | $ | ||||||||||||||||
21 | ||
| Shares | Weighted average exercise price per share | Weighted average remaining contractual life (in years) | |||||||||||||||
Outstanding at December 31, 2023 | $ | ||||||||||||||||
| Options exercised | ( | $ | |||||||||||||||
| Options cancelled/forfeited/expired | ( | $ | |||||||||||||||
Outstanding at September 30, 2024 | $ | ||||||||||||||||
Exercisable at September 30, 2024 | $ | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Matching Plan shares | $ | $ | $ | $ | |||||||||||||||||||
| Restricted stock units | |||||||||||||||||||||||
Stock options | |||||||||||||||||||||||
Total stock-based compensation | |||||||||||||||||||||||
| Less: stock-based compensation capitalized as software development costs | ( | ( | ( | ( | |||||||||||||||||||
Total stock-based compensation expense | $ | $ | $ | $ | |||||||||||||||||||
22 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Cost of revenue, net | $ | $ | $ | $ | |||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| General and administrative | |||||||||||||||||||||||
| Sales and marketing | |||||||||||||||||||||||
Total stock-based compensation expense | $ | $ | $ | $ | |||||||||||||||||||
23 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Numerator | |||||||||||||||||||||||
| Net loss, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
| Denominator | |||||||||||||||||||||||
| Weighted average shares of common stock used to compute net loss per share, basic and diluted | |||||||||||||||||||||||
| Net loss per share, basic and diluted | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
Weighted average stock options | |||||||||||||||||||||||
| Matching shares | |||||||||||||||||||||||
| Total | |||||||||||||||||||||||
24 | ||
25 | ||
26 | ||
27 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Expensify interchange amount | $ | 876 | $ | 3,090 | $ | 7,932 | $ | 8,008 | |||||||||||||||
| Vendor fees | (78) | (281) | (805) | (724) | |||||||||||||||||||
| Consideration from a vendor, net | $ | 798 | $ | 2,809 | $ | 7,127 | $ | 7,284 | |||||||||||||||
28 | ||
29 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands, except percentages, share and per share data) | |||||||||||||||||||||||
| Revenue | $ | 35,409 | $ | 36,494 | $ | 102,232 | $ | 115,479 | |||||||||||||||
Cost of revenue, net(1) | 17,145 | 17,680 | 46,091 | 50,380 | |||||||||||||||||||
| Gross margin | 18,264 | 18,814 | 56,141 | 65,099 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
Research and development(1) | 5,618 | 6,607 | 17,936 | 17,119 | |||||||||||||||||||
General and administrative(1) | 9,084 | 14,245 | 29,760 | 38,386 | |||||||||||||||||||
Sales and marketing(1) | 3,274 | 12,860 | 9,730 | 36,757 | |||||||||||||||||||
| Total operating expenses | 17,976 | 33,712 | 57,426 | 92,262 | |||||||||||||||||||
Income (loss) from operations | 288 | (14,898) | (1,285) | (27,163) | |||||||||||||||||||
| Other income (expenses), net | 181 | (2,375) | (1,033) | (5,158) | |||||||||||||||||||
| Income (loss) before income taxes | 469 | (17,273) | (2,318) | (32,321) | |||||||||||||||||||
| (Provision for) benefit from income taxes | (2,667) | 270 | (6,425) | (1,931) | |||||||||||||||||||
| Net loss | $ | (2,198) | $ | (17,003) | $ | (8,743) | $ | (34,252) | |||||||||||||||
| Net loss per share: | |||||||||||||||||||||||
| Basic and diluted | $ | (0.02) | $ | (0.21) | $ | (0.10) | $ | (0.42) | |||||||||||||||
| Weighted average shares of common stock used to compute net loss per share: | |||||||||||||||||||||||
| Basic and diluted | 88,177,739 | 82,469,190 | 86,643,209 | 82,085,508 | |||||||||||||||||||
| Net loss margin | (6) | % | (47) | % | (9) | % | (30) | % | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Cost of revenue, net | $ | 2,843 | $ | 3,312 | $ | 8,661 | $ | 10,218 | |||||||||||||||
| Research and development | 2,530 | 2,901 | 8,424 | 7,562 | |||||||||||||||||||
| General and administrative | 1,560 | 2,532 | 4,965 | 7,552 | |||||||||||||||||||
| Sales and marketing | 697 | 1,522 | 1,485 | 5,280 | |||||||||||||||||||
| Stock-based compensation expense | $ | 7,630 | $ | 10,267 | $ | 23,535 | $ | 30,612 | |||||||||||||||
30 | ||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Revenue | $ | 35,409 | $ | 36,494 | $ | (1,085) | (3) | % | |||||||||||||||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Cost of revenue, net | $ | 17,145 | $ | 17,680 | $ | (535) | (3) | % | |||||||||||||||
| Gross margin | $ | 18,264 | $ | 18,814 | $ | (550) | (3) | % | |||||||||||||||
| Gross margin % | 52 | % | 52 | % | |||||||||||||||||||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Research and development | $ | 5,618 | $ | 6,607 | $ | (989) | (15) | % | |||||||||||||||
31 | ||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| General and administrative | $ | 9,084 | $ | 14,245 | $ | (5,161) | (36) | % | |||||||||||||||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Sales and marketing | $ | 3,274 | $ | 12,860 | $ | (9,586) | (75) | % | |||||||||||||||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Other income (expenses), net | $ | 181 | $ | (2,375) | $ | 2,556 | (108) | % | |||||||||||||||
32 | ||
| Three Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| (Provision for) benefit from income taxes | $ | (2,667) | $ | 270 | $ | (2,937) | (1088) | % | |||||||||||||||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Revenue | $ | 102,232 | $ | 115,479 | $ | (13,247) | (11) | % | |||||||||||||||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Cost of revenue, net | $ | 46,091 | $ | 50,380 | $ | (4,289) | (9) | % | |||||||||||||||
| Gross margin | $ | 56,141 | $ | 65,099 | $ | (8,958) | (14) | % | |||||||||||||||
| Gross margin % | 55 | % | 56 | % | |||||||||||||||||||
33 | ||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Research and development | $ | 17,936 | $ | 17,119 | $ | 817 | 5 | % | |||||||||||||||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| General and administrative | $ | 29,760 | $ | 38,386 | $ | (8,626) | (22) | % | |||||||||||||||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Sales and marketing | $ | 9,730 | $ | 36,757 | $ | (27,027) | (74) | % | |||||||||||||||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Other income (expenses), net | $ | (1,033) | $ | (5,158) | $ | 4,125 | (80) | % | |||||||||||||||
34 | ||
| Nine Months Ended September 30, | Change | ||||||||||||||||||||||
| 2024 | 2023 | Amount | % | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Provision for income taxes | $ | (6,425) | $ | (1,931) | $ | (4,494) | 233 | % | |||||||||||||||
| Three Months Ended | Paid members | |||||||
September 30, 2024 | 684 | |||||||
September 30, 2023 | 719 | |||||||
35 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Adjusted EBITDA | $ | 9,676 | $ | (3,549) | $ | 26,982 | $ | 7,320 | |||||||||||||||
| Adjusted EBITDA margin | 27 | % | (10) | % | 26 | % | 6 | % | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
Non-GAAP net income (loss) | $ | 5,432 | $ | (6,736) | $ | 14,792 | $ | (3,640) | |||||||||||||||
Non-GAAP net income (loss) margin | 15 | % | (18) | % | 14 | % | (3) | % | |||||||||||||||
36 | ||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Net loss | $ | (2,198) | $ | (17,003) | $ | (8,743) | $ | (34,252) | |||||||||||||||
| Net loss margin | (6) | % | (47) | % | (9) | % | (30) | % | |||||||||||||||
| Add: | |||||||||||||||||||||||
| Provision for (benefit from) income taxes | 2,667 | (270) | 6,425 | 1,931 | |||||||||||||||||||
| Other (income) expenses, net | (181) | 2,375 | 1,033 | 5,158 | |||||||||||||||||||
| Depreciation and amortization | 1,758 | 1,082 | 4,732 | 3,871 | |||||||||||||||||||
| Stock-based compensation expense | 7,630 | 10,267 | 23,535 | 30,612 | |||||||||||||||||||
| Adjusted EBITDA | $ | 9,676 | $ | (3,549) | $ | 26,982 | $ | 7,320 | |||||||||||||||
| Adjusted EBITDA margin | 27 | % | (10) | % | 26 | % | 6 | % | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| Net loss | $ | (2,198) | $ | (17,003) | $ | (8,743) | $ | (34,252) | |||||||||||||||
| Net loss margin | (6) | % | (47) | % | (9) | % | (30) | % | |||||||||||||||
| Add: | |||||||||||||||||||||||
| Stock-based compensation expense | 7,630 | 10,267 | 23,535 | 30,612 | |||||||||||||||||||
Non-GAAP net income (loss) | $ | 5,432 | $ | (6,736) | $ | 14,792 | $ | (3,640) | |||||||||||||||
Non-GAAP net income (loss) margin | 15 | % | (18) | % | 14 | % | (3) | % | |||||||||||||||
37 | ||
| Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| (in thousands) | ||||||||||||||
| Net cash provided by operating activities | $ | 16,475 | $ | 2,102 | ||||||||||
| Net cash used in investing activities | (6,699) | (4,833) | ||||||||||||
| Net cash used in financing activities | (21,180) | (10,371) | ||||||||||||
| Net decrease in cash and cash equivalents and restricted cash | $ | (11,404) | $ | (13,102) | ||||||||||
38 | ||
39 | ||
40 | ||
41 | ||
42 | ||
43 | ||
44 | ||
45 | ||
46 | ||
| Total number of shares purchased | Weighted average price paid per share | Total number of shares purchased as part of publicly announced programs | Maximum number (or approximate dollar value) of shares that may yet be purchased under the program(1) | ||||||||||||||||||||
| July 1 - 31, 2024 | — | $ | — | — | $ | 41,000,003 | |||||||||||||||||
| August 1 - 31, 2024 | 645,938 | $ | 2.34 | 645,938 | $ | 39,490,003 | |||||||||||||||||
| September 1 - 30, 2024 | — | $ | — | — | $ | 39,490,003 | |||||||||||||||||
Three months ended September 30, 2024 | 645,938 | 645,938 | |||||||||||||||||||||
47 | ||
Trading Arrangement | |||||||||||||||||||||||||||||||||||
Action | Date | Rule 10b5-1(1) | Non-Rule 10b5-1(2) | Total Shares to be Sold | Expiration Date | ||||||||||||||||||||||||||||||
X | |||||||||||||||||||||||||||||||||||
X | |||||||||||||||||||||||||||||||||||
X | |||||||||||||||||||||||||||||||||||
48 | ||
| Incorporated by Reference | |||||||||||||||||||||||
| Exhibit No. | Name | Form | File No. | Exhibit | Filing Date | ||||||||||||||||||
3.1* | |||||||||||||||||||||||
| 3.2 | 8-K | 001-41043 | 3.2 | November 15, 2021 | |||||||||||||||||||
10.1* | |||||||||||||||||||||||
31.1* | |||||||||||||||||||||||
31.2* | |||||||||||||||||||||||
32.1** | |||||||||||||||||||||||
32.2** | |||||||||||||||||||||||
101.INS* | Inline XBRL Instance Document. | ||||||||||||||||||||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | ||||||||||||||||||||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | ||||||||||||||||||||||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | ||||||||||||||||||||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkable Document. | ||||||||||||||||||||||
104* | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||||||||||||||||||||
| * | Filed herewith. | |||||||||||||
| ** | Furnished herewith. The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. | |||||||||||||
49 | ||
EXPENSIFY, INC. | |||||||||||
Date: November 8, 2024 | By: | /s/ David Barrett | |||||||||
David Barrett | |||||||||||
President and Chief Executive Officer | |||||||||||
(Principal Executive Officer) | |||||||||||
Date: November 8, 2024 | By: | /s/ Ryan Schaffer | |||||||||
| Ryan Schaffer | |||||||||||
| Chief Financial Officer | |||||||||||
| (Principal Financial Officer) | |||||||||||